NCT00705835View on ClinicalTrials.gov

Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

rsPSMA protein plus Alhydrogel® vaccine

The assigned dose of rsPSMA protein plus Alhydrogel® vaccine will be administered subcutaneously to random sites on the upper arm and upper leg at weekly intervals for 3 weeks. This will be followed by a 4-week break and then a fourth vaccination during week 7. The vaccination site will rotate to a different quadrant with each administration.

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

PSMA Development Corp, LLC

UNKNOWN

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00705835 - Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel | Biotech Hunter | Biotech Hunter